- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NQF Offers Tool to Help Align Quality Efforts
Called the Community Tool to Align Measurement, the standards-setting organization notes that the tool can be used to compare measures, ensure providers are well-positioned for public and private payment incentives, identify measurement gaps and identify measures of interest for alignment, according to the NQF.
One part of the tool identifies the NQF-endorsed quality measures in use by the 16 members of the Robert Wood Johnson Foundation's Aligning Forces for Quality community alliances. The second part of the tool includes the experiences of the alliances in Cincinnati, Detroit and Maine, plus additional information.
In the spring, the NQF plans to work with at least two communities using the tool to try to improve it.
Source: Modern Healthcare
The National Quality Forum released a tool designed to assist states, communities and others with the alignment of quality measures and public reporting.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
